NCT04782895View on ClinicalTrials.gov

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

PHASE3CompletedINTERVENTIONAL

Enrollment

488

Participants

Timeline

Start Date

March 14, 2021

Primary Completion Date

May 30, 2022

Study Completion Date

July 25, 2022

Conditions

Cervical CancerCondylomata Acuminata

Interventions

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)

Three doses administered intramuscularly at 0, 45 day and 6 month.

BIOLOGICAL

Gardasil®9

Three doses administered intramuscularly at 0, 45 day and 6 month.

Trial Locations (1)

210009

Jiangsu Provincial Centre for Disease Control and Prevention, Nanjing

All Listed Sponsors

collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

INDUSTRY

lead

Xiamen University

OTHER

NCT04782895 - Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age | Biotech Hunter | Biotech Hunter